Can't find it...sure it would be nice to have a confirmation...let's see. Serious people involved here...that huge R/S it doesn't make any sense at these levels imho.
$EMGE Insight into the company's pending acquisition, merger, and the upcoming Spin-off of PHARMAZU IPO. This IPO will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION for EMGE shareholders.
Anyone who has traded 000's for a while knows that it's super rare to find a company poised for massive growth. Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%". This unique opportunity extends to the company's small share structure, boasting a market capitalization of only 490k. As of 01/30/2024, the outstanding shares (o/s) stand at 426 million, with 134 million restricted 292 unrestricted, and merely 220 million held at DTC. There has been no toxic dilution, as both the float and outstanding shares have remained unchanged for the past 9 months. This combination of impressive revenue potential, a compact share structure, and a lack of dilution positions this company as a compelling prospect for those seeking a promising investment opportunity and a potential bull run in 2024.
It's Official: Former L'Oreal President Jim Morrison Is Now Emergent Health Corporations. He's the CEO and transitioning to the role of Chairman of the Board at Emergent. Morrison has had a legendary career including numerous leadership positions in the personal care industry, most notably as President of L'Oréal. While at L'Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure.
1 - Emergent Medical Foods, Inc., a Wyoming corporation incorporated on April 4, 2019,
2 - Emergent OTC Products, Inc., a Wyoming corporation incorporated on August 1, 2019,
3 - PharmaZu, Inc., a Florida corporation incorporated on December 28, 2021.
4 - The Company acquired the assets and certain liabilities of Regen Biowellness, Inc. on August 2, 2022,
5 - Evolutionary Biologics, Inc., a Delaware corporation, acquired on August 15, 2022
Recent Events MERGER Agreement and SPIN-OFF of PHARMAZU
"As part of the roll-up being conducted by Boustead and Apollo Biowellness, effective June 1, 2023, Mr. Morrison will take over as President/CEO of Apollo Biowellness." From my point of view, Morrison taking over as President/CEO of Apollo Biowellness is a positive move. Transitioning to the role of Chairman of the Board at Emergent, his dual involvement with both companies positions him perfectly to coordinate with Boustead moving forward.
Upcoming SPIN-OFF PharmaZu IPO that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to the Emergent Shareholders.
MERGER IT'S OFFICIAL: Filing Name Changed Emergent Health Corp To Apollo Biowellness, Inc. According to the filings stated below, the R/S is no longer in effect after September 30, 2023.
ACQUISITION
This acquisition is highly favorable. We sell them the asset, and in return, we gain not less than 80% full control of their company. Just think about it—we haven't sold or lost anything in the process. That is the power of negotiation.
Keep in mind “BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) "Founded in 2020 by former L'Oreal President, Jim Morrison. Evolutionary Biologics is a supplier of cosmetic-focused biologics for plastic surgeons, dermatologists and medical spas across the United States.
This stock remains undiscovered by the masses. Additionally, very few are aware that the reverse split (r/s) is no longer in effect after September 30, 2023. I see extremely great value in the current situation. The merger is in progress, as of now, the name change has occurred, but the merger's official closure has not been announced. Typically, mergers and IPO spin-offs trigger a substantial increase in share prices. In this case, the merger will lead to the spin-off of Pharmazu, and shareholders will receive dividends in the form of an IPO. It's rare to encounter an opportunity to capture both a merger and an IPO. As per the news, the initial public offering of Emergent subsidiary PharmaZu common stock ("IPO") is set to be listed on NASDAQ or NYSE/AMEX, with no dilution for Emergent shareholders.
This is the end of part one. For part two I will offer an in-depth analysis of the management team, highlighting both their strengths and weaknesses. In part three, I'll uncover essential aspects like company revenue, services, patents, products, and market share. Stay tuned for a comprehensive examination that goes beyond the surface, covering every facet of this investment opportunity.